3-<methyl>pyridine | 120275-62-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-<methyl>pyridine
• 英文别名: 3-(N-(2-nitrobenzoyl)aminomethyl)pyridine；2-nitro-N-(pyridin-3-ylmethyl)benzamide
• CAS: 120275-62-9
• 化学式: C₁₃H₁₁N₃O₃
• mdl: MFCD00813633
• 分子量: 257.249
• InChiKey: JAFATDRGTMWFAM-UHFFFAOYSA-N

物化性质

• 沸点：
  502.6±40.0 °C(Predicted)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  87.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-<methyl>pyridine 在 sodium hydroxide 、 锌 作用下， 以 乙醇 为溶剂， 反应 9.0h， 以54%的产率得到2-(吡啶-3-基甲基)-1H-吲唑-3-酮
  参考文献：
  名称：

  Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity

  摘要：

  Since the hypothetical mechanisms of hydroperoxydation of arachidonic acid by, respectively, 5-lipoxygenase (5-LPO) and cyclooxygenase (CO) involve a redox cycle, a compound which reduces 5-LPO and CO to their inactive state would give a nonselective inhibitor of both enzymes. Structural modifications of such a compound could be expected to give improved potency and selectivity for 5-LPO and oral activity. Such an approach has led to the discovery of 1,2-dihydroindazol-3-ones which are potent 5-LPO inhibitors with various degrees of selectivity. Structure-activity relationship studies indicated that while N-1,N-2-unsubstituted and N-1-substituted derivatives are orally inactive, N-2-alkyl derivatives are orally active and inhibit both 5-LPO and CO. In contrast, N-2-benzyl derivatives are selective for 5-LPO but possess only weak oral activity. Further structural modifications have identified ICI 207968 [1,2-dihydro-2-(3-pyridylmethyl)-3H-indazol-3-one, 21a] which combines potent oral activity and high selectivity. Methemoglobin (MHb) induction by 21a in dog blood precluded its development for clinical use. Attempts at dissociating 5-LPO inhibitory properties and MHb formation showed that MHb formation in vitro seemed to be related to the redox potential of the compounds whereas 5-LPO inhibition was not. This study led to a series of 4-(N-n-pentylcarbamoyl)indazolinones which maintained in vitro 5-LPO potency but did not induce MHb.

  DOI：

  10.1021/jm00107a023
• 作为产物：
  描述：

  邻硝基苯甲酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 3-<methyl>pyridine
  参考文献：
  名称：

  Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity

  摘要：

  Since the hypothetical mechanisms of hydroperoxydation of arachidonic acid by, respectively, 5-lipoxygenase (5-LPO) and cyclooxygenase (CO) involve a redox cycle, a compound which reduces 5-LPO and CO to their inactive state would give a nonselective inhibitor of both enzymes. Structural modifications of such a compound could be expected to give improved potency and selectivity for 5-LPO and oral activity. Such an approach has led to the discovery of 1,2-dihydroindazol-3-ones which are potent 5-LPO inhibitors with various degrees of selectivity. Structure-activity relationship studies indicated that while N-1,N-2-unsubstituted and N-1-substituted derivatives are orally inactive, N-2-alkyl derivatives are orally active and inhibit both 5-LPO and CO. In contrast, N-2-benzyl derivatives are selective for 5-LPO but possess only weak oral activity. Further structural modifications have identified ICI 207968 [1,2-dihydro-2-(3-pyridylmethyl)-3H-indazol-3-one, 21a] which combines potent oral activity and high selectivity. Methemoglobin (MHb) induction by 21a in dog blood precluded its development for clinical use. Attempts at dissociating 5-LPO inhibitory properties and MHb formation showed that MHb formation in vitro seemed to be related to the redox potential of the compounds whereas 5-LPO inhibition was not. This study led to a series of 4-(N-n-pentylcarbamoyl)indazolinones which maintained in vitro 5-LPO potency but did not induce MHb.

  DOI：

  10.1021/jm00107a023

文献信息

• BRUNEAU, P.;DELVARE, C.;EDWARDS, M. P.;MCMILLAN, R. M., J. MED. CHEM. , 34,(1991) N, C. 1028-1036
  作者：BRUNEAU, P.、DELVARE, C.、EDWARDS, M. P.、MCMILLAN, R. M.

  DOI：——

  日期：——
• Therapeutic preparations
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0284174B1

  公开（公告）日：1992-07-29
• DERIVES D'AMINOPHENYLE PIPERAZINE OU D'AMINO PHENYLE PIPERIDINE INHIBITEURS DE PROTEINES PRENYL TRANSFERASE
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP1324999A1

  公开（公告）日：2003-07-09
• US5173496A
  申请人：——

  公开号：US5173496A

  公开（公告）日：1992-12-22
• [EN] NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME<br/>[FR] DERIVES D'AMINOPHENYLE PIPERAZINE OU D'AMINO PHENYLE PIPERIDINE INHIBITEURS DE PROTEINES PRENYL TRANSFERASE
  申请人：PF MEDICAMENT

  公开号：WO2002030927A1

  公开（公告）日：2002-04-18

  L'invention concerne des composés répondant à la formule générale (I), dans laquelle notamment : W représente : hydrogène, COR6, CSR6, SO2R6, CO(CH2)nR6, (CH2)nR7 ; X représente : CH ou N ; Y représente : (CH2)n, CO, CH2CO, CH=CHCO, CH2CH2CO ; Z représente un hétérocycle. Quand Z = pyridine alors Y est différent de CO. R1 représente : Hydrogène, C1-C6 alkyle, halogène, OCH3, CF3. R2 et R3, identiques ou différents représentent : Hydrogène, C1-C6 alkyle. R4 représente : a) Hydrogène ; b) C1-C6 alkyle ; c) un aryle ; d) un hétérocycle. R5 représente : Hydrogène, COR7, SO2R7, CO(CH2)nSR7, CO(CH2)nOR7, CONR7R8, CSNR7R8, CO(CH2)mCOR7. R6 représente : a) un phényle ou un naphtyle ; b) un C1-C6 alkyle, un cycloalkyle ; c) un hétérocycle ; d) NR7R8. R7 et R8, identiques ou différents, représentent : a) Hydrogène ; C1-C15 alkyle ; b) un hétérocycle ; c) un aryle. n représente : 0 à 10. m représente : 2 à 10 ; à la condition toutefois que, lorsque Z représente un groupement quinazoline ou benzimidazole, alors R5 est différent de CH2Ph ou Méthyl et n est différent de zéro.